Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

← catalyst calendar

NCT03409614 · results posted

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.

Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
789actual
Sites
133
Countries
Austria, China, France +15

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-03-06actualWhen the study began enrolling
Primary completion2025-02-27actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-02-27actualThe whole study's end, after follow-up
First posted2018-01-24actualWhen this record first appeared on the registry
Results posted2026-04-29actualWhen the sponsor posted results to the registry
Record updated2026-05-18actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Non-small Cell Lung Cancer

Interventions

  • Drug: REGN2810 — also filed as cemiplimab
  • Drug: REGN2810/chemo/ipi — also filed as cemiplimab
  • Other: Chemotherapy
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Part 1: Overall Survival (OS)
measured Up to a maximum of 82.2 months
Part 2: OS
measured Up to a maximum of 68.4 months

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2020-04-16 · 1.7 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-01-25 · 456 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed